| Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Allovir, Inc. | Director | Common Stock | 2.41M | $1.91M | $0.79 | Jun 6, 2024 | Direct |
| Marker Therapeutics, Inc. | President and CEO, Director | Employee Stock Option (right to buy) | 100K | May 10, 2023 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
|---|---|---|---|---|---|---|---|
| ALVR | Allovir, Inc. | Jun 6, 2024 | 1 | $0 | 4 | Jun 7, 2024 | Director |
| ALVR | Allovir, Inc. | May 11, 2023 | 1 | $0 | 4 | May 12, 2023 | Director |
| MRKR | Marker Therapeutics, Inc. | May 10, 2023 | 1 | $0 | 4 | May 11, 2023 | President and CEO, Director |
| MRKR | Marker Therapeutics, Inc. | Feb 27, 2023 | 1 | $0 | 4 | Mar 1, 2023 | Chief Scientific Officer & COO, Director |
| ALVR | Allovir, Inc. | May 17, 2022 | 1 | $0 | 4 | May 19, 2022 | Director |
| MRKR | Marker Therapeutics, Inc. | Mar 24, 2022 | 2 | -$16.2K | 4 | Mar 28, 2022 | Chief Scientific Officer & COO, Director |
| MRKR | Marker Therapeutics, Inc. | Feb 17, 2022 | 1 | $0 | 4 | Feb 22, 2022 | Chief Scientific Officer & COO, Director |
| ALVR | Allovir, Inc. | May 25, 2021 | 1 | $0 | 4 | May 27, 2021 | Director |